First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases

Jonathan Vöglein1,2 | Irena Kostova1 | Thomas Arzberger2,3,4 | Sigrun Roeber3 | Peer Schmitz3 | Mikael Simons2,5,6 | Viktoria Ruf3 | Otto Windl2,3 | Jochen Herms2,3,5 | Marianne Dieterich1,2,5,7 | Adrian Danek1,2 | Günter U. Höglinger2,5,6,8 | Armin Giese3 | Johannes Levin1,2,5

Abstract

Background and purpose: Clinical diagnostic criteria for neurodegenerative diseases have been framed based on clinical phenomenology. However, systematic knowledge about the first reported clinical symptoms in neurodegenerative diseases is lacking. Therefore, the aim was to determine the prevalence and clinical implications of the first clinical symptom (FS) as assessed by medical history in neuropathologically proven neurodegenerative diseases.

Methods: Neuropathological diagnoses from the Neurobiobank Munich, Germany, were matched with clinical records for analyses of the diagnostic and prognostic values of FSs.

Results: In all, 301 patients with the neuropathological diagnoses Alzheimer disease (AD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD), Lewy body disease (LBD) including the neuropathologically indistinguishable clinical phenotypes Parkinson disease and dementia with Lewy bodies, multiple system atrophy (MSA) and corticobasal degeneration (CBD) were studied. Memory disturbance was the most common FS in AD (34%), FTLD (19%) and LBD (26%), gait disturbance in PSP (35%) and MSA (27%) and aphasia and personality changes in CBD (20%, respectively). In a model adjusting for prevalence in the general population, AD was predicted by memory disturbance in 79.0%, aphasia in 97.2%, personality changes in 96.0% and by cognitive disturbance in 99.0%. Gait disturbance and tremor predicted LBD in 54.6% and 97.3%, coordination disturbance MSA in 59.4% and dysarthria FTLD in 73.0%. Cognitive FSs were associated with longer survival in AD (12.0 vs. 5.3 years; \( p < 0.001 \)) and FTLD (8.2 vs. 4.1 years; \( p = 0.005 \)) and motor FSs with shorter survival in PSP (7.2 vs. 9.7; \( p = 0.048 \)).

Conclusions: Assessing FSs in neurodegenerative diseases may be beneficial for accuracy of diagnosis and prognosis and thereby may improve clinical care and precision of study recruitment.

KEYWORDS
diagnosis, first clinical symptom, neurodegenerative diseases, prognosis
INTRODUCTION

Neuropathological examination is the gold standard for diagnosis of neurodegenerative diseases, despite recent advances in the development of in vivo biomarkers [1–4]. This applies for the common neurodegenerative diseases such as Alzheimer’s disease (AD) [3,5], the neuropathologically defined entity Lewy body disease (LBD) including the neuropathologically indistinguishable clinical diagnoses Parkinson disease (PD) [6,7] and dementia with Lewy bodies (DLB) [8], as well as for the rarer conditions progressive supranuclear palsy (PSP) [9], frontotemporal lobar degeneration (FTLD) [10–12], multiple system atrophy (MSA) [13] and corticobasal degeneration (CBD) [14]. In clinical settings, the most prominent symptom in early disease stages serves as the guiding symptom in most cases, since several cognitive, behavioral and motor symptoms are present at later stages of neurodegenerative diseases, complicating clinical diagnosing [15,16].

Whereas there is extensive literature about clinical manifestations of neurodegenerative diseases [3,6,8–11,13,14,17,47,48], to our knowledge the first evident clinical symptom of the aforementioned diseases has not been systematically assessed to date. In addition, evidence with respect to associations between the first symptom and the course of neurodegenerative diseases is lacking. Hence, the intention was to investigate the distribution of first symptoms in patients with neuropathologically confirmed neurodegenerative diseases. Clinical diagnostic criteria are overlapping and do not allow for an exclusive diagnosis in several cases, in particular in advanced disease stages when several symptoms that are common in different neurodegenerative diseases are present. Therefore, the aim was to analyze a potential added differential diagnostic value of the first clinical symptom. Further, it was intended to investigate associations between the first symptom and survival.

METHODS

Participants

Data from the Neurobiobank Munich (NBM) located at the Center for Neuropathology and Prion Research and from clinical records from the hospital of the Ludwig-Maximilians-Universität München, Munich, and other academic hospitals in Germany were used for this study. All participants with sufficient clinical data who underwent autopsy between 1985 and 2017 and had a neuropathological diagnosis of AD, LBD, PSP (FTLD-tau PSP), FTLD (FTLD-TDP, FTLD-UPS, aFTLD-U, FTLD-IF, BIBD, FTLD-tau PiD, FTLD-ni), MSA or CBD (FTLD-tau CBD [18]) were included. The paper refers to the neuropathologically defined entity Lewy body disease (LBD), which is the corresponding neuropathological diagnosis of both the clinical diagnosis Parkinson disease (PD) and the clinical diagnosis dementia with Lewy bodies (DLB). The neuropathological examination cannot distinguish between the clinical phenotypes PD and DLB.

The study was approved by the Institutional Review Board of the Ludwig-Maximilians-Universität München, Munich, Germany. All NBM cases were collected according to the guidelines of the local ethics committee. The study conforms with the World Medical Association Declaration of Helsinki.

Neuropathological procedures

Brain banking was performed according to established procedures using a standardized protocol [19]. All neuropathological diagnoses were reviewed and confirmed or revised by two senior neuropathologists experienced in neurodegenerative diseases in consensus according to current neuropathological diagnostic criteria [5,7–9,12–14,18,20,21]. If more than one disease-specific neuropathological change was present, current neuropathological diagnostic criteria and preponderance of pathology determined diagnosis. Neuropathological diagnosis, date of birth, date of death, age at death and sex were transferred to a standardized template.

Clinical evaluation

First clinical symptom and time of onset of the first clinical symptom were extracted from digital and paper medical records and entered in the standardized template. Assessment of the first symptom was based on medical history including third-party information (i.e., relatives, caregivers) as provided in clinical records. Thus, evaluation was based on patient or third-party reported symptoms during a formal clinician-led assessment in the scope of a clinical presentation. For determination of the first symptom and the time of its onset information from medical histories in all available clinical records was taken into account and integrated. The time of onset of the first symptom was defined as the time when the first persistent symptom that was attributed to the disease by the respective clinicians occurred. Speech problems are referred to as dysarthria and language problems as aphasia in the paper. Clinical data were discussed and assessed in consensus by two senior neurologists experienced in the clinical care of neurodegenerative diseases (JV, JL). JV and JL were blinded to neuropathological diagnoses.

Data processing and statistical analyses

A template that merged neuropathological and clinical data was created using FileMaker Pro (Filemaker Inc.). Clinical and demographic features of the study population were analyzed and compared between subgroups using Pearson’s chi-squared test for categorical variables and one-way analysis of variance for continuous variables. The Games–Howell test was used for post hoc analysis. The distribution of first symptoms in every neurodegenerative disease was analyzed. Further, the distribution of neurodegenerative diseases for each first clinical symptom was investigated for symptoms with
RESULTS

Participants

The NBM comprised 978 cases at the time of analyses. Of these, 301 individuals with the neuropathological diagnoses AD, PSP, FTLD, LBD (which includes the clinical phenotypes of PD and DLB), MSA or CBD and sufficient medical history data on first symptoms were identified and included in the study. The remaining NBM cases had either a neuropathological diagnosis other than AD, PSP, FTLD, LBD, MSA or CBD, or sufficient clinical information to determine the first clinical symptom was not available. 89 (29.6%) of the included cases had AD, 72 (23.9%) PSP, 47 (15.6%) FTLD, 47 (15.6%) LBD, 26 (8.6%) MSA and 20 (6.6%) CBD. Age at death and survival differed significantly amongst the neurodegenerative diseases. Further details of study population characteristics are provided in Table 1.

Distribution of first clinical symptoms in neurodegenerative diseases

Thirty-seven first clinical symptoms were extracted from medical records. The detailed distribution of first symptoms of the neurodegenerative diseases studied here is depicted in Figure 1 and Table S1. Memory disturbance was the most common first symptom of patients with AD, LBD and FTLD. Patients with PSP and MSA most frequently presented gait disturbance first. Individuals suffering from CBD most commonly presented equally often with aphasia and personality changes first. There was no statistically significant difference in frequency of the first symptom gait disturbance between

---

**TABLE 1** Clinical, neuropathological and demographic features of the study participants

|                | AD (n = 89) | PSP (n = 72) | FTLD (n = 47) | LBD (n = 47) | MSA (n = 26) | CBD (n = 20) | Total (n = 301) | p value |
|----------------|-------------|--------------|---------------|--------------|--------------|---------------|----------------|---------|
| Female sex, n (%) | 48 (54.5) | 32 (44.4) | 18 (39.1) | 17 (36.2) | 13 (50.0) | 9 (45.0) | 137 (45.8) | 0.35    |
| Mean age at onset ± SD, years | 63.0 (13.1) | 63.9 (7.6) | 57.9 (12.9) | 63.9 (13.3) | 58.4 (10.5) | 60.1 (7.7) | 62.0 (11.7) | 0.0301 |
| Mean age at death (SD), years | 74.1 (12.7) | 71.9 (6.2) | 64.0 (11.3) | 77.5 (7.2) | 66.1 (9.2) | 66.5 (8.0) | 71.4 (10.8) | <0.0012 |
| Mean survival (SD), years | 10.9 (7.3) | 8.2 (4.5) | 6.4 (6.6) | 13.8 (11.6) | 7.8 (3.4) | 6.6 (4.1) | 9.5 (7.5) | <0.0013 |

Notes: Categorical variables were compared between groups using Pearson’s chi-squared test and continuous variables using one-way analysis of variance. p values below 0.05 were considered statistically significant and are italicized. For statistically significant between-groups differences the Games–Howell test was performed for pairwise comparisons of differences in means.

Abbreviations: AD, Alzheimer disease; CBD, corticobasal degeneration; FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy.

1No statistically significant differences were found in post hoc pairwise comparisons.

2Mean age of death was statistically significantly greater (i) in AD compared to FTLD, MSA and CBD, (ii) in PSP compared to FTLD and (iii) in LBD compared to PSP, FTLD, MSA and CBD.

3Mean survival was statistically significantly longer (i) in AD compared to PSP, FTLD, MSA and CBD and (ii) in LBD compared to PSP, FTLD, MSA and CBD. There was no statistically significant difference in age at death or survival between AD and LBD.

LBD refers to the neuropathologically defined entity Lewy body disease that includes the neuropathologically indistinguishable clinical phenotypes of Parkinson disease and dementia with Lewy bodies.
the MSA cases with cerebellar (n = 9) and parkinsonian (n = 15) predominance types, as gait disturbance occurred in 2/9 (22.2%) patients with cerebellar and in 4/15 (26.7%) cases with a parkinsonian predominance type (p = 1.0; Fisher’s exact test).

Probabilities for individual neurodegenerative diseases by first clinical symptom in the general population

A comprehensive overview of neurodegenerative diagnoses that are predicted by the prevalence adjusted model to follow individual first clinical symptoms in the general population is given in Figure 2. Based on this model, which stipulates that one of the neurodegenerative diseases studied here is the neuropathological diagnosis, the first symptoms memory disturbance, aphasia, personality changes and cognitive disturbance led by far the most frequently to an AD diagnosis in the general population. Gait disturbance and tremor as first symptoms are predicted to be most frequently followed by an LBD diagnosis. Coordination disturbance most commonly precedes MSA and dysarthria FTLD.

Diagnostic accuracy of first symptoms in the study population

Orientation disturbance occurred solely in AD patients as the first clinical symptom (in 5.6%). This results in a 100% specificity and
100% positive predictive value regarding a neuropathological diagnosis of AD in this study. Sensitivity was low (5.6%). The first symptom circumscribed weakness was only present in FTLD patients (in 10.6%) resulting in a 100% specificity and 100% positive predictive value with respect to a neuropathological diagnosis of FTLD. Sensitivity was 10.6%. Dizziness as the first symptom occurred exclusively in PSP (in 4.2%) and MSA (in 7.7%). This leads to a 100% specificity and 100% positive predictive value of dizziness.
regarding diagnoses of PSP or MSA in this population. Sensitivity was low (5.1%).

**Differential diagnostic performance of first clinical symptoms in pairwise comparisons**

The first symptoms memory disturbance, gait disturbance, aphasia, personality changes, cognitive disturbance and coordination disturbance could distinguish between several neurodegenerative diseases in pairwise comparisons. Tremor and dysarthria as first clinical symptoms did not allow for distinguishing between any neurodegenerative diseases. Details with respect to the differential diagnostic performance of first symptoms in pairwise comparisons are given in Figure 3.

**First clinical symptom and survival**

Alzheimer disease patients who showed any cognitive symptom as the earliest symptom \( (n = 74; 84.1\%) \) had a significantly longer survival compared to AD patients with non-cognitive first symptoms \( (12.0 \text{ vs. } 5.3 \text{ years}; p < 0.001) \). In PSP, any motor symptom as the clinical first symptom \( (n = 44; 62.0\%) \) was associated with a shorter survival \( (7.2 \text{ vs. } 9.7 \text{ years in patients with non-motor first symptoms}; p = 0.048) \). FTLD patients who had any cognitive symptom as the first symptom \( (n = 25; 56.8\%) \) exhibited a longer survival compared to patients with non-cognitive first symptoms \( (8.2 \text{ vs. } 4.1 \text{ years}; p = 0.005) \). There was no association between the respective most frequent supergroup symptom (i.e., any cognitive symptom or any motor symptom) and survival in LBD, MSA and CBD (Figure 4).

**FIGURE 3** Cross-comparisons of prevalences of the most common first symptoms between the neurodegenerative diseases in the study. For cross-comparisons of symptom prevalences between neurodegenerative diseases Pearson’s chi-squared test or Fisher's exact test, where appropriate, were used. In the case of a statistically significant difference in frequency of a distinct symptom between the respective diseases, its abbreviating letter is highlighted in grey. If the symptom was more frequent in a neurodegenerative disease listed in the left column, it was highlighted dark gray. If the symptom was more frequent in a neurodegenerative disease listed in the top row, it was highlighted light gray. The Benjamini–Hochberg method was used to adjust for multiple testing. \( p \) values below 0.05 were considered statistically significant. LBD refers to the neuropathologically defined entity Lewy body disease that includes the neuropathologically indistinguishable clinical phenotypes of Parkinson disease and dementia with Lewy bodies. A, aphasia; AD, Alzheimer disease; C, cognitive disturbance; CBD, corticobasal degeneration; D, dysarthria; FTLD, frontotemporal lobar degeneration; G, gait disturbance; K, coordination disturbance; LBD, Lewy body disease; M, memory disturbance; MSA, multiple system atrophy; P, personality changes; PSP, progressive supranuclear palsy; T, tremor.
DISCUSSION

In our study cohort of patients with neuropathologically diagnosed neurodegenerative diseases, memory disturbance was the most frequent first clinical symptom in three of six diseases (AD, FTLD and the neuropathologically defined entity LBD [which includes the clinical phenotypes of PD and DLB]) and gait disturbance in two of six diseases (PSP and MSA). Aphasia and personality changes were most common in CBD.

Unexpectedly, memory disturbance was the most common first symptom in FTLD, a disease with the cardinal symptoms language and behavioral disturbance, whose current diagnostic criteria [10,11] do not involve an early memory predominant phenotype and in the case of primary progressive aphasia even consider it an exclusionary criterion [10]. Surprisingly memory disturbance was the second most frequent clinical first symptom in PSP. Although PSP is known to cause a variety of phenotypes including cognitive phenotypes, a memory predominant phenotype is not represented in current PSP.

FIGURE 4 Comparisons of survival based on the presence of cognitive or motor first symptoms. Comparisons of survival between patients with any cognitive symptom and patients with non-cognitive symptoms as the first clinical symptom in Alzheimer disease (AD), frontotemporal lobar degeneration (FTLD) and corticobasal degeneration (CBD), and between patients with any motor symptom and patients with non-motor symptoms as the first clinical symptom in progressive supranuclear palsy (PSP), Lewy body disease (LBD) and multiple system atrophy (MSA). For comparisons the most frequent supergroup symptom, that is, any cognitive symptom or any motor symptom, in each neurodegenerative disease was chosen. In AD and FTLD, patients with any cognitive symptom as the first clinical symptom had a longer survival compared to patients who showed non-cognitive symptoms first. PSP patients who developed any motor symptom as the first clinical symptom showed a shorter survival compared to patients who exhibited non-motor symptoms first. ***p < 0.001; **p < 0.01; *p < 0.05. p values below 0.05 were considered statistically significant. Error bars represent 95% confidence intervals. LBD refers to the neuropathologically defined entity Lewy body disease that includes the neuropathologically indistinguishable clinical phenotypes of Parkinson disease and dementia with Lewy bodies.
criteria [9] and was not described in two larger series of neuropathologically confirmed PSP cases [32,33]. This suggests an added value of assessing the first clinical symptom beyond general clinical presentation and may inspire a very early memory predominant phenotype to be discussed for the diagnostic criteria of FTLD and PSP.

In the model adjusted for prevalences of neurodegenerative diseases in the general population, aphasia as the first clinical symptom is predicted to be by far the most frequent followed by a neuropathological diagnosis of AD. This finding highlights the importance of an atypical AD presentation with a primary progressive aphasia phenotype as a differential diagnosis for an underlying AD pathology [10]. Further, personality changes as the first clinical symptom is predicted to lead substantially more often to a diagnosis of AD than to a diagnosis FTLD that includes a behavioral variant [11]. This seems to render the cardinal symptoms of FTLD, aphasia and behavioral symptoms, not suitable as first clinical symptoms to distinguish between AD and FTLD. This assumption is corroborated by the pairwise comparisons of this study (Figure 3) and emphasizes the need for thorough neuropsychological testing and biomarker evaluation for establishing a diagnosis.

Gait disturbance as the first symptom was predicted to be followed by an AD diagnosis in a relevant percentage whereas tremor was not predicted to be followed by a neuropathological diagnosis of AD in the prevalence adjusted model (Figure 2). This finding is in accordance with a recent study that revealed a bradykinetic profile of motor symptoms in AD [16].

Despite emerging evidence that cognitive disturbance is an integral part of MSA [34], only 4% of MSA patients showed a cognitive symptom, concentration disturbance, as the first clinical symptom. MSA stood out to have by far the smallest portion of cognitive symptoms as the first clinical symptom (Figure 1). In this study, the most common cognitive first symptoms memory disturbance, aphasia and personality changes were never followed by a neuropathological diagnosis of MSA.

Psychosis including hallucinations was very rare and sleep disturbance absent as the first symptom in LBD in this study. This is remarkable, as these symptoms are core clinical features of DLB, besides Parkinson disease one of the two principal phenotypes of LBD, as defined by current diagnostic criteria [8]. Also remarkable, the core clinical features of CBD [14]/CBS (corticobasal syndrome) [9] apraxia, alien limb phenomena, myoclonus and dystonia, did not occur as first clinical symptom in CBD in the current study (Figure 1). These findings may emphasize an added benefit of assessing the first clinical symptom and suggest the use of the first symptom to support differential diagnostic thinking in addition to established diagnostic criteria.

The first symptom orientation disturbance featured a very high accuracy to predict AD, circumscribed weakness to predict FTLD and dizziness to predict PSP or MSA in our study. These symptoms line up with other early clinical symptoms that were shown to be highly accurate for disease prediction in AD: seizures and dysdiadochokinesia [16,35].

For the common constellation that clinicians hover between two neurodegenerative diagnoses the pairwise comparison of neurodegenerative diseases with respect to the first clinical symptom performed in this study may facilitate accurate diagnosis.

For example, although cognitive phenotypes of PSP and CBD are common [9,14], memory and cognitive disturbance as the first symptom allowed for the differentiation between AD and PSP and memory disturbance between AD and CBD.

Further, gait disturbance as the first symptom enabled AD to be distinguished from all neurodegenerative diseases with primary motor phenotype (PSP, LBD and MSA) even though motor symptoms are known to be a common and early feature of AD [16,36]. Whilst motor phenotypes such as amyotrophic lateral sclerosis, CBS and PSP syndromes are common in FTLD [37], gait disturbance as the first symptom allowed for delineation between FTLD and PSP.

Multiple system atrophy could be distinguished from all other diseases except CBD by coordination disturbance as the first symptom. This may reflect the frequent cerebellar phenotype in MSA [13] but also is remarkable as patients may also perceive basal ganglia motor symptoms as coordination problems. The perception of basal ganglia symptoms as coordination disturbance may be the reason that this symptom allows for differentiation between AD and CBD.

Personality changes as first symptom distinguished FTLD from LBD, a differentiation that may be tricky if LBD presents with its primary cognitive phenotype DLB. Additionally, personality changes as the first symptom enabled CBD to be distinguished from LBD and MSA which could be a challenge because of the heterogeneous clinical presentation of CBD [14].

Tremor as the first symptom did not allow for differentiation between any neurodegenerative diseases, interestingly not even between diseases with primary motor manifestation, in particular LBD that includes the clinical phenotype Parkinson disease, and primary cognitive diseases such as AD and FTLD (Figure 3).

Several factors that are associated with survival in neurodegenerative diseases have been identified to date, including genetic factors, demographic data and biomarkers in AD [38,39] and FTLD [40–42] and genetic factors in PSP [43]. However, to our knowledge there is limited evidence about associations of clinical parameters with survival in neurodegenerative diseases. Clinical parameters bear the advantage of a time- and cost-effective assessment. It is revealed here that any cognitive symptom as the first clinical symptom in AD and FTLD was associated with a longer survival, whereas any motor symptom as the first symptom was associated with a shorter survival in PSP. This knowledge may be useful to estimate prognosis in clinical and research settings by thorough exploration of the first clinical symptom alone.

The strengths of this study are the large size for a clinical-neuropathological correlation study that includes neurodegenerative diseases other than AD, the definite diagnosis of neurodegenerative diseases by neuropathological examination, a comprehensive neuropathological evaluation by two experienced senior neuropathologists in consensus preventing inter-rater variability, the standardized consensual assessment of clinical data,
and the standardized neuropathological and clinical evaluation of six common neurodegenerative diseases promoting comparability. Limitations are small numbers in the groups of the rare neurodegenerative diseases MSA and CBD and the retrospective extraction of clinical data from medical records. A prospective investigation including larger numbers for rare neurodegenerative diseases is warranted. In CBD, some of the cases that were attributed the first symptom aphasia could have had speech apraxia which is a common clinical presentation in CBD. A further limitation is that the initial symptoms were not recorded with a standardized questionnaire. Grouping together symptoms into motor and cognitive supergroups could be a potential limitation as specific motor or non-motor features that have previously been shown to be clinical predictors of progression may not be appropriately represented, for example early dysphagia [44] and early autonomic features in PSP [45]. An important question that has to be addressed in future work is whether first symptoms may help to differentiate between specific subtypes of diseases which are challenging to distinguish in the early stages of disease, as has been done recently in a prospective study with small numbers of PSP and CBS patients [46].

In summary, this clinical-neuropathological association study shed light on the distribution of first clinical symptoms in the six frequent neurodegenerative diseases AD, PSP, FTLD, LBD, MSA and CBD. Standardized assessment of the first clinical symptom may facilitate correct diagnosis and prognosis in a time- and cost-effective manner and may prevent patients from more invasive and expensive diagnostic interventions. The clinical implications of first symptoms could be considered in addition to current diagnostic criteria or even inform future revisions. Therefore, awareness of the first clinical symptom in neurodegenerative diseases may improve clinical care and facilitate precise recruitment for clinical studies.

ACKNOWLEDGEMENTS
The authors thank Christian Haass, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany, for proofreading the paper and for providing valuable input. This work was funded by the German Center for Neurodegenerative Diseases (DZNE) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198). The altruism of the study participants and their relatives is gratefully acknowledged. Open Access funding enabled and organized by Projekt DEAL.

Jonathan Vöglein reports no disclosures. Irena Kostova reports no disclosures. Thomas Arzberger reports no disclosures. Sigrun Roeber reports no disclosures. Peer Schmitz reports no disclosures. Mikael Simons reports no disclosures. Viktoria Ruf reports no disclosures. Otto Windl reports no disclosures. Jochen Herms reports no disclosures. Marianne Dieterich reports no disclosures. Adrian Danek reports no disclosures. Günter Höglinger has ongoing research collaborations with Prothena; served/serves as a scientific advisor for Abbvie, Alzprotekt, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, UCB. Armin Giese reports no disclosures. Johannes Levin reports personal fees from Aesku, personal fees from Bayer Vital, personal fees with Willi Gross Foundation, personal fees from Axon Neuroscience, personal fees from Ionis Pharmaceuticals, personal fees from Roche, non-financial support from Abbvie, compensation from MODAG GmbH for work as CMO outside the submitted work.

AUTHOR CONTRIBUTIONS
Jonathan Vöglein: Conceptualization (lead); data curation (lead); formal analysis (lead); funding acquisition (lead); investigation (lead); methodology (lead); project administration (lead); resources (lead); software (lead); supervision (equal); validation (lead); visualization (lead); writing original draft (lead); writing review and editing (lead). Irena Kostova: Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); resources (equal); software (equal); writing review and editing (equal). Sigrun Roeber: Data curation (equal); investigation (equal); resources (equal); writing review and editing (equal). Peer Schmitz: Data curation (equal); methodology (equal); resources (equal); software (equal); writing review and editing (equal). Mikael Simons: Investigation (equal); validation (equal); writing review and editing (equal). Viktoria Ruf: Data curation (equal); investigation (equal); resources (equal); writing review and editing (equal). Otto Windl: Data curation (equal); investigation (equal); resources (equal); writing review and editing (equal). Jochen Herms: Data curation (equal); investigation (equal); resources (equal); writing review and editing (equal). Adrian Danek: Investigation (equal); resources (equal); writing review and editing (equal). GU Höglinger: Investigation (equal); writing review and editing (equal). Armin Giese: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); resources (equal); writing review and editing (equal). Johannes Levin: Conceptualization (lead); data curation (equal); formal analysis (lead); funding acquisition (lead); investigation (lead); methodology (lead); project administration (lead); resources (lead); software (equal); supervision (lead); validation (lead); visualization (lead); writing review and editing (lead).

ORCID
Jonathan Vöglein https://orcid.org/0000-0002-5965-838X

REFERENCES
1. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. https://doi.org/10.1097/NEN.0b013e31824b211b
4. Pan XD, Chen XC. Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. *Transl Neurodegener*. 2013;2(1):8. https://doi.org/10.1186/2047-9158-2-8

5. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. *Acta Neuropathol*. 2012;123(1):1-11. https://doi.org/10.1007/s00401-011-0910-3

6. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. *Move Disord*. 2015;30(12):1591-1601. https://doi.org/10.1002/mds.26424

7. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. *Lancet Neurol*. 2009;8(12):1150-1157. https://doi.org/10.1016/s1474-4223(09)70238-8

8. McKeith IG, Boeve BF, Dickson DW, et al. Diagnostic and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88-100. https://doi.org/10.1212/wnl.0000000000004058

9. Högländer GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. *Move Disord*. 2017;32(6):853-864. https://doi.org/10.1002/mds.26987

10. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76(11):1006-1014. https://doi.org/10.1212/wnl.0b013e31821103e6

11. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134(Pt 9):2456-2477. https://doi.org/10.1093/brain/awr179

12. Cairns NJ, Bigio EH, Mackenzie IRA, et al. Neuropathologic diagnostoic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol*. 2007;114(1):5-22. https://doi.org/10.1007/s00401-007-0237-2

13. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology*. 2008;71(9):670-676. https://doi.org/10.1212/01.wnl.000024625.00404.15

14. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology*. 2013;80(5):496-503. https://doi.org/10.1212/01.wnl.00004138216.2870f3d1

15. Tang M, Ryman DC, McDade E, et al. Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). *Lancet Neurol*. 2016;15(13):1317-1325. https://doi.org/10.1016/s1474-422d(16)30229-0

16. Vöglein J, Paumier K, Jucker M, et al. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease. *Brain*. 2019;142(5):1429-1440. https://doi.org/10.1093/brain/awz050

17. Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria—2015. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;16(5-6):291-292. https://doi.org/10.3109/21678421.2015.1049183

18. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathol*. 2009;117(1):15-18. https://doi.org/10.1007/s00401-008-0460-5

19. Kretzschmar H. Brain banking: opportunities, challenges and meaning for the future. *Nat Rev Neurosci*. 2009;10(1):70-78. https://doi.org/10.1038/nrn2535

20. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. *Alzheimer’s Dement*. 2012;8(1):1-13. https://doi.org/10.1016/j.jalz.2011.10.007

21. Hauw J-J, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). *Neurology*. 1994;44(11):2015. https://doi.org/10.1212/wnl.44.11.2015

22. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. *Neurology*. 2013;80(19):1778-1783. https://doi.org/10.1212/WNL.0b013e31828726f5

23. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. *Neurology*. 1997;49(5):1284-1288. https://doi.org/10.1212/wnl.49.5.1284

24. Coyle-Gilchrist ITS, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. *Neurology*. 2016;86(18):1736-1743. https://doi.org/10.1212/wnl.0000000000002638

25. Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago, Japan. *Move Disord*. 2004;19(10):1239-1240. https://doi.org/10.1002/mds.20149

26. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. *Lancet (London, England)*. 1999;354(9192):1771-1775. https://doi.org/10.1016/s0140-6736(99)01437-9

27. Onyike CU, Diedrich-Cle-Mich J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry*. 2013;25(2):130-137. https://doi.org/10.3109/09540261.2013.776523

28. Galvin E. Lewy body dementia. *Prac Neurol*. 2019;1:67-71.

29. Pringsheim T, Jette N, Frolik A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. *Move Disord*. 2014;29(13):1583-1590. https://doi.org/10.1002/mds.25945

30. Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. *Lancet (London, England)*. 2000;355(9202):495-496. https://doi.org/10.1016/s0140-6736(00)80205-4

31. Togasaki DM, Tanner CM. Epidemiologic aspects. *Adv Neurol*. 2000;82:53-59.

32. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. *Move Disord*. 2014;29(14):1758-1766. https://doi.org/10.1002/mds.26054

33. Kovacs GC, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. *Acta Neuropathol*. 2020;140(1):99-119. https://doi.org/10.1007/s00401-020-02158-2

34. Stankovic I, Krsmer F, Jecic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Move Disord*. 2014;29(7):857-867. https://doi.org/10.1002/mds.25880

35. Vöglein J, Noachtar S, McDade E, et al. Seizures as an early symptom of autosomal dominant Alzheimer’s disease. *Neurobiol Aging*. 2019;76:18-23. https://doi.org/10.1016/j.neurobiolaging.2018.11.022

36. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer’s disease. *Alzheimer’s Dement*. 2015;11(1):70-98. https://doi.org/10.1016/j.jalz.2014.04.514
37. Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. *Acta Neuropathol*. 2015;129(4):469-491. https://doi.org/10.1007/s00401-014-1380-1

38. Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. *Alzheimer’s Dement*. 2019;15(7):888-898. https://doi.org/10.1016/j.jalz.2019.04.001

39. Armstrong RA. Factors determining disease duration in Alzheimer’s disease: a postmortem study of 103 cases using the Kaplan–Meier estimator and Cox regression. *Biomed Res Int*. 2014;2014:623487. https://doi.org/10.1155/2014/623487

40. Gittings LM, Boeynaems S, Lightwood D, et al. Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity. *Acta Neuropathol*. 2020;139(2):407-410. https://doi.org/10.1007/s00401-019-02104-x

41. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2020;19(2):145-156. https://doi.org/10.1016/S1474-4422(19)30394-1

42. El-Wahsh S, Finger EC, Piguet O, et al. Predictors of survival in frontotemporal lobar degeneration syndromes. *J Neurol Neurosurg Psychiatry*. 2021;92:425-433. https://doi.org/10.1136/jnnp-2020-324349

43. Jabbari E, Koga S, Valentino RR, et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. *Lancet Neurol*. 2021;20(2):107-116. https://doi.org/10.1016/S1474-4422(20)30394-x

44. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. *J Neurol Neurosurg Psychiatry*. 1996;60(6):615-620. https://doi.org/10.1136/jnnp.60.6.615

45. Oliveira MCB, Ling H, Lees AJ, Holton JL, De Pablo-Fernandez E, Warner TT. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. 2019;90(5):555-561. https://doi.org/10.1136/jnnp-2018-319374

46. Jabbari E, Holland N, Chelban V, et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. *JAMA Neurol*. 2020;77(3):377-387. https://doi.org/10.1001/jama.2019.4347

47. Vöglein J, Ricard I, Noachtar S, et al. Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course. *J Neurol*. 2020;267(10):2941-2948. http://dx.doi.org/10.1007/s00415-020-09937-7

48. Vöglein J, Willem M, Trambauer J, et al. Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid-β processing effects. *Neurobiol Aging*. 2019;84:241.e5-241.e11. http://dx.doi.org/10.1016/j.neurobiolaging.2019.08.034

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

Table S1

How to cite this article: Vöglein J, Kostova I, Arzberger T, et al. First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. *Eur J Neurol*. 2021;28:1801-1811. https://doi.org/10.1111/ene.14800